EPISODE · Jan 9, 2023 · 8 MIN
FDA approves second Alzheimer’s treatment
from POLITICO's Pulse Check · host POLITICO
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug. Learn more about your ad choices. Visit megaphone.fm/adchoices
What this episode covers
On Friday, the FDA granted accelerated approval to Leqembi, previously known as lecanemab, made by Eisai and Biogen. The drug is the second that targets amyloid proteins in the brain, which are thought to cause progressive dementia. Katherine Ellen Foley talks with Megan Messerly about the future of the drug. Learn more about your ad choices. Visit megaphone.fm/adchoices
NOW PLAYING
FDA approves second Alzheimer’s treatment
No transcript for this episode yet
Similar Episodes
Jun 20, 2026 ·2m
Jun 20, 2026 ·2m
Jun 15, 2026 ·3m
Jun 15, 2026 ·3m
Jun 14, 2026 ·2m
Jun 14, 2026 ·2m